Our Pipeline

Diverse Pipeline of First-in-Class Aesthetic and Dermatological Solutions

Veradermics is advancing a robust pipeline of product candidates designed to address high-value dermatologic conditions with limited proven solutions, combining proven mechanisms with innovative formulations intended to optimize efficacy, safety, and patient convenience, starting with pattern hair loss - a condition impacting over 80 million people in the US alone.*

PROGRAM INDICATION

MOA Delivery

PRE-IND

PHASE 1

PHASE 2

PHASE 3

VDPHL01

Pattern Hair Loss
(Androgenetic Alopecia)

Minoxidil
Extended-Release
Oral Tablet

Phase 3 Trials Ongoing – Male and Female

*Source: MedlinePlus.gov – Genetics, Androgenetic Alopecia, July 2023: 50M Men, 30M Women.

PATTERN HAIR LOSS